GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intelligent Bio Solutions Inc (NAS:INBS) » Definitions » EBITDA per Share

Intelligent Bio Solutions (Intelligent Bio Solutions) EBITDA per Share : $-56.21 (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Intelligent Bio Solutions EBITDA per Share?

Intelligent Bio Solutions's EBITDA per Share for the three months ended in Mar. 2024 was $-1.26. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-56.21.

During the past 3 years, the average EBITDA per Share Growth Rate was -21.00% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -3.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Intelligent Bio Solutions's EBITDA per Share or its related term are showing as below:

INBS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -21   Med: -12.3   Max: 1.6
Current: -21

During the past 7 years, the highest 3-Year average EBITDA per Share Growth Rate of Intelligent Bio Solutions was 1.60% per year. The lowest was -21.00% per year. And the median was -12.30% per year.

INBS's 3-Year EBITDA Growth Rate is ranked worse than
82.51% of 709 companies
in the Medical Devices & Instruments industry
Industry Median: 8 vs INBS: -21.00

Intelligent Bio Solutions's EBITDA for the three months ended in Mar. 2024 was $-2.62 Mil.

During the past 3 years, the average EBITDA Growth Rate was -51.30% per year. During the past 5 years, the average EBITDA Growth Rate was -15.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 7 years, the highest 3-Year average EBITDA Growth Rate of Intelligent Bio Solutions was -7.40% per year. The lowest was -51.30% per year. And the median was -9.00% per year.


Intelligent Bio Solutions EBITDA per Share Historical Data

The historical data trend for Intelligent Bio Solutions's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelligent Bio Solutions EBITDA per Share Chart

Intelligent Bio Solutions Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EBITDA per Share
Get a 7-Day Free Trial -143.19 -63.61 -138.77 -136.49 -112.79

Intelligent Bio Solutions Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -63.77 -23.26 -10.76 -20.94 -1.26

Intelligent Bio Solutions EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Intelligent Bio Solutions's EBITDA per Share for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA per Share(A: Jun. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=-9.474/0.084
=-112.79

Intelligent Bio Solutions's EBITDA per Share for the quarter that ended in Mar. 2024 is calculated as

EBITDA per Share(Q: Mar. 2024 )
=EBITDA/Shares Outstanding (Diluted Average)
=-2.617/2.080
=-1.26

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-56.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intelligent Bio Solutions  (NAS:INBS) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Intelligent Bio Solutions EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Intelligent Bio Solutions's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Intelligent Bio Solutions (Intelligent Bio Solutions) Business Description

Traded in Other Exchanges
Address
57th Street, 142 West, 11th Floor, New York, NY, USA, 10019
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana.
Executives
Harry Simeonidis director, officer: CEO, President 708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Foundation Ma-ran 10 percent owner 1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
Gary W. Rollins Foundation 10 percent owner 1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
David A Jenkins director P.O. BOX 682838, PARK CITY UT 84068
Jason Isenberg director 1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
Spiro Kevin Sakiris officer: Chief Financial Officer 708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Life Science Biosensor Diagnostics Pty Ltd 10 percent owner LEVEL 9, 85 CASTLEREAGH STREET, SYDNEY C3 2000
Tom Parmakellis director 708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Victoria Gavrilenko director 708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
Christopher Towers director 1981 MARCUS AVENUE, SUITE 130, LAKE SUCCESS NY 11042
Lawrence B Fisher director C/0 FINANCIAL FEDERAL CORP, 733 THIRD AVENUE, NEW YORK NY 10017
Leonard Victor Kempler director 708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
George Margelis director 708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Boyages Steven Constantine director 708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
Jonathan Scott Hurd director 708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017

Intelligent Bio Solutions (Intelligent Bio Solutions) Headlines

From GuruFocus

Intelligent Bio Solutions Reaches Key Milestone in Biosensor Platform Development

By Stock market mentor Stock market mentor 01-23-2023